BCL2L11 and AL amyloidosis: Moreover, dasatinib has been shown to reduce MDR1 and Survivin levels; increase Bim levels; and restore adriamycin, vincristine, dexamethasone, and melphalan sensitivity in drug-resistant multiple myeloma cells [32].